Abstract
Multiple myeloma (MM) is an incurable hematological cancer that affects mainly older adults. Patients are exposed to the use of multiple drugs to treat other comorbidities in addition to MM, increasing the burden of antineoplastic treatment. Thus, the objective of this chapter is to present (i) the main drug classes and single drugs approved for the MM treatment; (ii) relevant issues related to the effectiveness and safety of MM therapy and quality of life; and (iii) the use of multiple drugs by MM patients in an aging context.
MM therapy has evolved with the introduction of immunomodulatory drugs, proteasome inhibitors, histone deacetylase inhibitors, and nuclear export inhibitors and immunotherapy (monoclonal antibodies, antibody-drug conjugate, and CAR T cell therapy). The development of drugs for the treatment of relapsed/refractory MM is still a challenge. Supportive therapy of MM usually characterizes polypharmacy and exposes patients to potentially inappropriate medication, fall risk–increasing drugs, drugs that induce osteoporosis or fracture and drugs with anticholinergic activity.
MM therapy has markedly increased the survival of MM patients. Supportive medications can be harmful for older adults with MM and should be reviewed considering their frailty level. Valuable tools can help to evaluate medication burden, adherence, adverse events, and health-related quality of life (HRQoL) in research and clinical practice.
This is a preview of subscription content, log in via an institution to check access.
References
Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ et al (1993) The European organization for research and treatment of cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 85(5):365–376. https://doi.org/10.1093/jnci/85.5.365
Abramson HN (2023) Recent advances in the applications of small molecules in the treatment of multiple myeloma. Int J Mol Sci 24(3). https://doi.org/10.3390/ijms24032645
AGS (2023) By the American Geriatrics Society 2023 updated AGS beers criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc 71(7):2052–2081. https://doi.org/10.1111/jgs.18372
Anderson SM, Beck B, Sterud S, Lockhorst R, Ngorsuraches S (2019) Evaluating the use of appropriate anticoagulation with lenalidomide and pomalidomide in patients with multiple myeloma. J Oncol Pharm Pract 25(4):806–812. https://doi.org/10.1177/1078155218758500
Bahk JH, Jo WL, Kwon SY, Park HC, Lim YW (2023) Weight-based bisphosphonate administration for multiple myeloma patients and the risks of skeletal complications. J Clin Med 12(4). https://doi.org/10.3390/jcm12041637
Bahlis NJ, Siegel DS, Schiller GJ, Samaras C, Sebag M, Berdeja J et al (2022) Pomalidomide, dexamethasone, and daratumumab immediately after lenalidomide-based treatment in patients with multiple myeloma: updated efficacy, safety, and health-related quality of life results from the phase 2 MM-014 trial. Leuk Lymphoma 63(6):1407–1417. https://doi.org/10.1080/10428194.2022.2030477
Baker HA, Brown AR, Mahnken JD, Shireman TI, Webb CE, Lipe BC (2019) Application of risk factors for venous thromboembolism in patients with multiple myeloma starting chemotherapy, a real-world evaluation. Cancer Med 8(1):455–462. https://doi.org/10.1002/cam4.1927
Bao L, Wang Y-T, Lu M-q, Zhuang J, Chu B, Shi L et al (2022) Validation of the Impede VTE score for prediction of venous thromboembolism in Chinese patients with multiple myeloma: a retrospective cohort study. Blood 140(Supplement 1):5146–5147. https://doi.org/10.1182/blood-2022-168633
Barlow A, Prusak ES, Barlow B, Nightingale G (2021) Interventions to reduce polypharmacy and optimize medication use in older adults with cancer. J Geriatr Oncol 12(6):863–871. https://doi.org/10.1016/j.jgo.2020.12.007
Basch E, Reeve BB, Mitchell SA, Clauser SB, Minasian LM, Dueck AC et al (2014) Development of the National Cancer Institute’s patient-reported outcomes version of the common terminology criteria for adverse events (PRO-CTCAE). J Natl Cancer Inst 106(9). https://doi.org/10.1093/jnci/dju244
Bates SE (2011) Multiple myeloma. Clin Cancer Res 17(6):1224. https://doi.org/10.1158/1078-0432.Ccr-11-0294
Batteux B, Bennis Y, Bodeau S, Masmoudi K, Hurtel-Lemaire AS, Kamel S et al (2021) Associations between osteoporosis and drug exposure: a post-marketing study of the World Health Organization pharmacovigilance database (VigiBase®). Bone 153:116137. https://doi.org/10.1016/j.bone.2021.116137
Bernstein ZS, Kim EB, Raje N (2022) Bone disease in multiple myeloma: biologic and clinical implications. Cells 11(15). https://doi.org/10.3390/cells11152308
Black N (2013) Patient reported outcome measures could help transform healthcare. BMJ 346:f167. https://doi.org/10.1136/bmj.f167
Burwick N, Sharma S (2019) Glucocorticoids in multiple myeloma: past, present, and future. Ann Hematol 98(1):19–28. https://doi.org/10.1007/s00277-018-3465-8
Calafiore V, Giamporcaro S, Conticello C, Romano A, Parisi M, Giuffrida G et al (2020) A real-life survey of venous thromboembolic events occurring in myeloma patients treated in third line with second-generation novel agents. J Clin Med 9(9). https://doi.org/10.3390/jcm9092876
Carrière I, Farré A, Norton J, Wyart M, Tzourio C, Noize P et al (2016) Patterns of selective serotonin reuptake inhibitor use and risk of falls and fractures in community-dwelling elderly people: the Three-City cohort. Osteoporos Int 27(11):3187–3195. https://doi.org/10.1007/s00198-016-3667-7
Chaudhry V, Cornblath DR, Corse A, Freimer M, Simmons-O’Brien E, Vogelsang G (2002) Thalidomide-induced neuropathy. Neurology 59(12):1872–1875. https://doi.org/10.1212/01.wnl.0000037480.59194.85
Chiu E, Cabanero M, Sidhu G (2020) Paradoxical stress fracture in a patient with multiple myeloma and bisphosphonate use. Cureus 12(8):e9837. https://doi.org/10.7759/cureus.9837
Cocks K, Cohen D, Wisløff F, Sezer O, Lee S, Hippe E et al (2007) An international field study of the reliability and validity of a disease-specific questionnaire module (the QLQ-MY20) in assessing the quality of life of patients with multiple myeloma. Eur J Cancer 43(11):1670–1678. https://doi.org/10.1016/j.ejca.2007.04.022
Costa IHF, Menezes de Pádua CA, Drummond PLM, Silveira LP, Malta JS, Santos RMM, Reis AMM (2023) Comparison of three risk assessment models for thromboembolism in multiple myeloma patients receiving immunomodulators: a Brazilian historical cohort. J Thromb Thrombolysis 56(1):147–155. https://doi.org/10.1007/s11239-023-02817-7
Covut F, Ahmed R, Chawla S, Ricaurte F, Samaras CJ, Anwer F et al (2021) Validation of the IMPEDE VTE score for prediction of venous thromboembolism in multiple myeloma: a retrospective cohort study. Br J Haematol 193(6):1213–1219. https://doi.org/10.1111/bjh.17505
Cowan AJ, Allen C, Barac A, Basaleem H, Bensenor I, Curado MP et al (2018) Global burden of multiple myeloma: a systematic analysis for the global burden of disease study 2016. JAMA Oncol 4(9):1221–1227. https://doi.org/10.1001/jamaoncol.2018.2128
Cowan AJ, Baldomero H, Atsuta Y, Mikhael J, Aljurf M, Seber A et al (2020) The global state of hematopoietic cell transplantation for multiple myeloma: an analysis of the worldwide network of blood and marrow transplantation database and the global burden of disease study. Biol Blood Marrow Transplant 26(12):2372–2377. https://doi.org/10.1016/j.bbmt.2020.08.018
Cowan AJ, Green DJ, Kwok M, Lee S, Coffey DG, Holmberg LA et al (2022) Diagnosis and management of multiple Myeloma: a review. JAMA 327(5):464–477. https://doi.org/10.1001/jama.2022.0003
Cransac A, Aho S, Chretien ML, Giroud M, Caillot D, Boulin M (2019) Adherence to immunomodulatory drugs in patients with multiple myeloma. PLoS One 14(3):e0214446. https://doi.org/10.1371/journal.pone.0214446
Curado MP, Oliveira MM, Silva DRM, Souza DLB (2018) Epidemiology of multiple myeloma in 17 Latin American countries: an update. Cancer Med 7(5):2101–2108. https://doi.org/10.1002/cam4.1347
D’Oronzo S, Stucci S, Tucci M, Silvestris F (2015) Cancer treatment-induced bone loss (CTIBL): pathogenesis and clinical implications. Cancer Treat Rev 41(9):798–808. https://doi.org/10.1016/j.ctrv.2015.09.003
Dashputre AA, Gatwood KS, Gatwood J (2020) Medication adherence, health care utilization, and costs among patients initiating oral oncolytics for multiple myeloma or chronic lymphocytic leukemia/small lymphocytic lymphoma. J Manag Care Spec Pharm 26(2):186–196. https://doi.org/10.18553/jmcp.2020.26.2.186
De Geest S, Zullig LL, Dunbar-Jacob J, Helmy R, Hughes DA, Wilson IB, Vrijens B (2018) ESPACOMP medication adherence reporting guideline (EMERGE). Ann Intern Med 169(1):30–35. https://doi.org/10.7326/m18-0543
Dempsey JL, Johns A, Rosko AE, Lazarus HM (2019) The pharmacologic management of multiple myeloma in older adults. Expert Opin Pharmacother 20(7):887–902. https://doi.org/10.1080/14656566.2019.1577822
Dimopoulos MA, Moreau P, Terpos E, Mateos MV, Zweegman S, Cook G et al (2021) Multiple myeloma: EHA-ESMO clinical practice guidelines for diagnosis, treatment and follow-up(†). Ann Oncol 32(3):309–322. https://doi.org/10.1016/j.annonc.2020.11.014
Drummond PLM, Santos RMM, Silveira LP, Malta JS, Reis AMM, Costa NL et al (2023) Chemotherapy-induced peripheral neuropathy impacts quality of life and activities of daily living of Brazilian multiple myeloma patients. Curr Drug Saf. https://doi.org/10.2174/1574886318666230817162424
Elias E, Targownik LE (2019) The Clinician’s guide to proton pump inhibitor related adverse events. Drugs 79(7):715–731. https://doi.org/10.1007/s40265-019-01110-3
EMA (2023) European medicines agency. https://www.ema.europa.eu/en/medicines. Accessed 02 Nov 2023
Fattahi MR, Niknam R, Shams M, Anushiravani A, Taghavi SA, Omrani GR, Mahmoudi L (2019) The association between prolonged proton pump inhibitors use and bone mineral density. Risk Manag Healthc Policy 12:349–355. https://doi.org/10.2147/rmhp.S223118
FDA (2023) Food drug administration. Drugs@FDA: FDA-Approved Drugs. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm. Accessed 02 Nov 2023
Feng X, Higa GM, Safarudin F, Sambamoorthi U, Chang J (2020) Prevalence and factors associated with potentially inappropriate medication use in older medicare beneficiaries with cancer. Res Social Adm Pharm 16(10):1459–1471. https://doi.org/10.1016/j.sapharm.2019.12.018
Filho RJPM, Crusoe E, Riva E, Bujan W, Conte G, Navarro Cabrera JR et al (2019) Analysis of availability and access of anti-myeloma drugs and impact on the management of multiple myeloma in Latin American countries. Clin Lymphoma Myeloma Leuk 19(1):e43–e50. https://doi.org/10.1016/j.clml.2018.08.005
Fillmore NR, DuMontier C, Yildirim C, La J, Epstein MM, Cheng D et al (2021) Defining multimorbidity and its impact in older United States veterans newly treated for multiple myeloma. J Natl Cancer Inst 113(8):1084–1093. https://doi.org/10.1093/jnci/djab007
Florence CS, Bergen G, Atherly A, Burns E, Stevens J, Drake C (2018) Medical costs of fatal and nonfatal falls in older adults. J Am Geriatr Soc 66(4):693–698. https://doi.org/10.1111/jgs.15304
Fotiou D, Gavriatopoulou M, Terpos E (2020) Multiple myeloma and thrombosis: prophylaxis and risk prediction tools. Cancers (Basel) 12(1). https://doi.org/10.3390/cancers12010191
Gellad WF, Thorpe CT, Steiner JF, Voils CI (2017) The myths of medication adherence. Pharmacoepidemiol Drug Saf 26(12):1437–1441. https://doi.org/10.1002/pds.4334
Gerlach LB, Wiechers IR, Maust DT (2018) Prescription benzodiazepine use among older adults: a critical review. Harv Rev Psychiatry 26(5):264–273. https://doi.org/10.1097/hrp.0000000000000190
Ghobrial IM, Rajkumar SV (2003) Management of thalidomide toxicity. J Support Oncol 1(3):194–205
Gimenes HT, Zanetti ML, Haas VJ (2009) Factors related to patient adherence to antidiabetic drug therapy. Rev Lat Am Enfermagem 17(1):46–51. https://doi.org/10.1590/s0104-11692009000100008
Gliklich RE, Dreyer NA, Leavy MB (2014) Use of patient-reported outcomes in registries. In: Gliklich RE, Dreyer NA, Leavy MB (eds) Registries for evaluating patient outcomes: a user’s guide [Internet], 3rd edn. Agency for Healthcare Research and Quality (US), Rockville (MD). https://www.ncbi.nlm.nih.gov/books/NBK208628/
Guan Q, Men S, Juurlink DN, Bronskill SE, Wunsch H, Gomes T (2022) Opioid initiation and the hazard of falls or fractures among older adults with varying levels of central nervous system depressant burden. Drugs Aging 39(9):729–738. https://doi.org/10.1007/s40266-022-00970-x
Guio J, Melo A, Saldarriaga MM, Fuentes C, Tíjaro-Ovalle N, Borda A et al (2023) A novel digital educational strategy improves treatment adherence and quality of life in patients with multiple myeloma. J Cancer Educ:1–8. https://doi.org/10.1007/s13187-023-02374-w
Guyatt GH, Feeny DH, Patrick DL (1993) Measuring health-related quality of life. Ann Intern Med 118(8):622–629. https://doi.org/10.7326/0003-4819-118-8-199304150-00009
Hamm J, Money AG, Atwal A, Paraskevopoulos I (2016) Fall prevention intervention technologies: a conceptual framework and survey of the state of the art. J Biomed Inform 59:319–345. https://doi.org/10.1016/j.jbi.2015.12.013
Hevroni G, Korde N (2022) Examining health related quality of life outcomes in multiple myeloma: past and future perspectives. Semin Oncol 49(1):94–102. https://doi.org/10.1053/j.seminoncol.2022.01.002
Hochman MJ, Kamal AH, Wolf SP, Samsa GP, Currow DC, Abernethy AP, LeBlanc TW (2016) Anticholinergic drug burden in noncancer versus cancer patients near the end of life. J Pain Symptom Manag 52(5):737–743.e733. https://doi.org/10.1016/j.jpainsymman.2016.03.020
Hungria VTM, Chiattone C, Pavlovsky M, Abenoza LM, Agreda GP, Armenta J et al (2019a) Epidemiology of hematologic malignancies in real-world settings: findings from the Hemato-oncology Latin America observational registry study. J Glob Oncol 5:1–19. https://doi.org/10.1200/jgo.19.00025
Hungria VTM, Lee JH, Maiolino A, de Queiroz CE, Martinez G, Bittencourt R et al (2019b) Survival differences in multiple myeloma in Latin America and Asia: a comparison involving 3664 patients from regional registries. Ann Hematol 98(4):941–949. https://doi.org/10.1007/s00277-019-03602-4
Hussain M, Yellapragada S, Al Hadidi S (2023) Differential diagnosis and therapeutic advances in multiple myeloma: a review article. Blood Lymphat Cancer 13:33–57. https://doi.org/10.2147/blctt.S272703
IHME (2015) Institute for Health Metrics and Evaluation (IHME). GBD compare. Seattle: IHME, University of Washington. https://www.healthdata.org/. Accessed 15 Nov 2023
João C, Geraldes C, Neves M, Mariz M, Trigo F (2020) Management of older and frail patients with multiple myeloma in the Portuguese routine clinical practice: deliberations and recommendations from an expert panel of hematologists. J Geriatr Oncol 11(8):1210–1216. https://doi.org/10.1016/j.jgo.2020.06.002
Kantilal K, Kantilal K, Nightingale G, Ramsdale E (2022) How-to guide for medication reviews in older adults with cancer: a Young International Society of Geriatric Oncology and Nursing & Allied Health Interest Group initiative. J Geriatr Oncol 13(8):1283–1286. https://doi.org/10.1016/j.jgo.2022.05.012
Kaweme NM, Changwe GJ, Zhou F (2021) Approaches and challenges in the management of multiple myeloma in the very old: future treatment prospects. Front Med (Lausanne) 8:612696. https://doi.org/10.3389/fmed.2021.612696
Kerckhove N, Collin A, Condé S, Chaleteix C, Pezet D, Balayssac D, Guastella V (2018) Chemotherapy-induced peripheral neuropathy: symptomatology and epidemiology. Bull Cancer 105(11):1020–1032. https://doi.org/10.1016/j.bulcan.2018.07.009
Kumar SK, Vij R, Noga SJ, Berg D, Brent L, Dollar L, Chari A (2017) Treating multiple myeloma patients with oral therapies. Clin Lymphoma Myeloma Leuk 17(5):243–251. https://doi.org/10.1016/j.clml.2017.02.024
Larocca A, Cani L, Bertuglia G, Bruno B, Bringhen S (2023) New strategies for the treatment of older myeloma patients. Cancers (Basel) 15(10). https://doi.org/10.3390/cancers15102693
Lavrador M, Castel-Branco MM, Cabral AC, Veríssimo MT, Figueiredo IV, Fernandez-Llimos F (2021) Association between anticholinergic burden and anticholinergic adverse outcomes in the elderly: pharmacological basis of their predictive value for adverse outcomes. Pharmacol Res 163:105306. https://doi.org/10.1016/j.phrs.2020.105306
Lee C, Grigorian M, Nolan R, Binder G, Rice G (2016) A retrospective study of direct cost to patients associated with the use of oral oncology medications for the treatment of multiple myeloma. J Med Econ 19(4):397–402. https://doi.org/10.3111/13696998.2015.1130710
Lee J, Negm A, Peters R, Wong EKC, Holbrook A (2021a) Deprescribing fall-risk increasing drugs (FRIDs) for the prevention of falls and fall-related complications: a systematic review and meta-analysis. BMJ Open 11(2):e035978. https://doi.org/10.1136/bmjopen-2019-035978
Lee JH, Lim J, Han SJ, do Moon S, Moon H, Lee SY et al (2021b) Clinical outcomes associated with anticholinergic burden in older hospitalized patients with advanced cancer: a single-center database study. Support Care Cancer 29(8):4607–4614. https://doi.org/10.1007/s00520-021-06008-z
Leonard GD, Wright MA, Quinn MG, Fioravanti S, Harold N, Schuler B et al (2005) Survey of oxaliplatin-associated neurotoxicity using an interview-based questionnaire in patients with metastatic colorectal cancer. BMC Cancer 5:116. https://doi.org/10.1186/1471-2407-5-116
Li A, Wu Q, Luo S, Warnick GS, Zakai NA, Libby EN et al (2019) Derivation and validation of a risk assessment model for immunomodulatory drug-associated thrombosis among patients with multiple myeloma. J Natl Compr Cancer Netw 17(7):840–847. https://doi.org/10.6004/jnccn.2018.7273
Li T, Timmins HC, Lazarus HM, Park SB (2020a) Peripheral neuropathy in hematologic malignancies – past, present and future. Blood Rev 43:100653. https://doi.org/10.1016/j.blre.2020.100653
Li T, Timmins HC, King T, Kiernan MC, Goldstein D, Park SB (2020b) Characteristics and risk factors of bortezomib induced peripheral neuropathy: a systematic review of phase III trials. Hematol Oncol 38(3):229–243. https://doi.org/10.1002/hon.2706
Lima MSR, Menezes de Pádua CA, Drummond PLM, Silveira LP, Malta JS, Santos RMM, Reis AMM (2023) Health-related quality of life and use of medication with anticholinergic activity in patients with multiple myeloma. Support Care Cancer 31(7):379. https://doi.org/10.1007/s00520-023-07835-y
Lisibach A, Benelli V, Ceppi MG, Waldner-Knogler K, Csajka C, Lutters M (2021) Quality of anticholinergic burden scales and their impact on clinical outcomes: a systematic review. Eur J Clin Pharmacol 77(2):147–162. https://doi.org/10.1007/s00228-020-02994-x
Machado TRL, Menezes de Pádua CA, Miranda Drummond PL, Silveira LP, Malta JS, Santos RMM, et al. (2023) Factors associated with potentially inappropriate medications in elderly with multiple myeloma. J Oncol Pharm Pract:10781552231190009. https://doi.org/10.1177/10781552231190009
Malta JS, Silveira LP, Drummond PLM, Costa NL, Santos RMM, Reis IA et al (2021) Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma. Curr Med Res Opin 37(7):1163–1169. https://doi.org/10.1080/03007995.2021.1929136
Malta JS, Drummond PLM, Silveira LP, Costa NL, Santos RMM, Machado CJ et al (2022) Effect of therapeutic regimens and polypharmacy on health-related quality of life of people with multiple myeloma: a cross-sectional study in Belo Horizonte. Brazil Curr Med Res Opin 38(8):1275–1283. https://doi.org/10.1080/03007995.2022.2034387
Marcum ZA, Gellad WF (2012) Medication adherence to multidrug regimens. Clin Geriatr Med 28(2):287–300. https://doi.org/10.1016/j.cger.2012.01.008
Martin BC, Wiley-Exley EK, Richards S, Domino ME, Carey TS, Sleath BL (2009) Contrasting measures of adherence with simple drug use, medication switching, and therapeutic duplication. Ann Pharmacother 43(1):36–44. https://doi.org/10.1345/aph.1K671
Martin T, Lin Y, Agha M, Cohen AD, Htut M, Stewart AK et al (2022) Health-related quality of life in patients given ciltacabtagene autoleucel for relapsed or refractory multiple myeloma (CARTITUDE-1): a phase 1b–2, open-label study. Lancet Haematol 9(12):e897–e905. https://doi.org/10.1016/S2352-3026(22)00284-8
Martinelli F, Quinten C, Maringwa JT, Coens C, Vercauteren J, Cleeland CS et al (2011) Examining the relationships among health-related quality-of-life indicators in cancer patients participating in clinical trials: a pooled study of baseline EORTC QLQ-C30 data. Expert Rev Pharmacoecon Outcomes Res 11(5):587–599. https://doi.org/10.1586/erp.11.51
Mian H, Fiala M, Wildes TM (2020) Adherence to Lenalidomide in older adults with newly diagnosed multiple myeloma. Clin Lymphoma Myeloma Leuk 20(2):98–104.e101. https://doi.org/10.1016/j.clml.2019.09.618
Mohamed MR, Ramsdale E, Loh KP, Arastu A, Xu H, Obrecht S et al (2020) Associations of polypharmacy and inappropriate medications with adverse outcomes in older adults with cancer: a systematic review and meta-analysis. Oncologist 25(1):e94–e108. https://doi.org/10.1634/theoncologist.2019-0406
Mohty B, El-Cheikh J, Yakoub-Agha I, Moreau P, Harousseau JL, Mohty M (2010) Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations. Haematologica 95(2):311–319. https://doi.org/10.3324/haematol.2009.012674
Mohyuddin GR, Koehn K, Abdallah AO, Sborov DW, Rajkumar SV, Kumar S, McClune B (2021) Use of endpoints in multiple myeloma randomized controlled trials over the last 15 years: a systematic review. Am J Hematol 96(6):690–697. https://doi.org/10.1002/ajh.26166
Mokkink LB, Prinsen CAC, Bouter LM, Vet HCW, Terwee CB (2016) The COnsensus-based Standards for the selection of health Measurement INstruments (COSMIN) and how to select an outcome measurement instrument. Braz J Phys Ther 20(2):105–113
Moore DC, Oxencis CJ, Shank BR (2022) New and emerging pharmacotherapies for the management of multiple myeloma. Am J Health Syst Pharm 79(14):1137–1145. https://doi.org/10.1093/ajhp/zxac091
Morris R, Lewis A (2020) Falls and cancer. Clin Oncol (R Coll Radiol) 32(9):569–578. https://doi.org/10.1016/j.clon.2020.03.011
Mosaad M, Elnaem MH, Cheema E, Ibrahim I, Ab Rahman J, Kori AN, Hin HS (2021) Cancer-associated thrombosis: a clinical scoping review of the risk assessment models across solid tumours and haematological malignancies. Int J Gen Med 14:3881–3897. https://doi.org/10.2147/ijgm.S320492
Naser AY, Ofori-Asenso R, Awawdeh SA, Qadus S, Alwafi H, Liew D (2022) Real world adherence to and persistence with oral oncolytics in multiple myeloma: a systematic review and meta-analysis. Clin Lymphoma Myeloma Leuk 22(10):760–773. https://doi.org/10.1016/j.clml.2022.05.003
NCCN (2023a) National comprehensive cancer network guidelines version 1.2023 older adult oncology. https://www.nccn.org/login?ReturnURL=https://www.nccn.org/professionals/physician_gls/pdf/senior.pdf. Accessed 02 Nov 2023
NCCN (2023b) National comprehensive cancer network guidelines version 2.2024 multiple myeloma. https://www.nccn.org/guidelines/recently-published-guidelines. Accessed 02 Nov 2023
NCI (2017) National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) Version 5.0. 2017. https://ctep.cancer.gov/protocolDevelopment/electronic_applications/docs/CTCAE_v5_Quick_Reference_5x7.pdf. Accessed 10 Nov 2023
Nightingale G, Hajjar E, Swartz K, Andrel-Sendecki J, Chapman A (2015) Evaluation of a pharmacist-led medication assessment used to identify prevalence of and associations with polypharmacy and potentially inappropriate medication use among ambulatory senior adults with cancer. J Clin Oncol 33(13):1453–1459. https://doi.org/10.1200/jco.2014.58.7550
Nightingale G, Mohamed MR, Holmes HM, Sharma M, Ramsdale E, Lu-Yao G, Chapman A (2021) Research priorities to address polypharmacy in older adults with cancer. J Geriatr Oncol 12(6):964–970. https://doi.org/10.1016/j.jgo.2021.01.009
O’Mahony D, Cherubini A, Guiteras AR, Denkinger M, Beuscart JB, Onder G et al (2023) STOPP/START criteria for potentially inappropriate prescribing in older people: version 3. Eur Geriatr Med 14(4):625–632. https://doi.org/10.1007/s41999-023-00777-y
Osterberg L, Blaschke T (2005) Adherence to medication. N Engl J Med 353(5):487–497. https://doi.org/10.1056/NEJMra050100
Palmaro A, Rougé-Bugat ME, Gauthier M, Despas F, Moulis G, Lapeyre-Mestre M (2017) Real-life practices for preventing venous thromboembolism in multiple myeloma patients: a cohort study from the French health insurance database. Pharmacoepidemiol Drug Saf 26(5):578–586. https://doi.org/10.1002/pds.4180
Patrick DL, Burke LB, Powers JH, Scott JA, Rock EP, Dawisha S et al (2007) Patient-reported outcomes to support medical product labeling claims: FDA perspective. Value Health 10(Suppl 2):S125–S137. https://doi.org/10.1111/j.1524-4733.2007.00275.x
Poly TN, Islam MM, Yang HC, Wu CC, Li YJ (2019) Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies. Osteoporos Int 30(1):103–114. https://doi.org/10.1007/s00198-018-4788-y
Postma TJ, Aaronson NK, Heimans JJ, Muller MJ, Hildebrand JG, Delattre JY et al (2005) The development of an EORTC quality of life questionnaire to assess chemotherapy-induced peripheral neuropathy: the QLQ-CIPN20. Eur J Cancer 41(8):1135–1139. https://doi.org/10.1016/j.ejca.2005.02.012
Qin X, Hung J, Knuiman MW, Briffa TG, Teng TK, Sanfilippo FM (2020) Comparison of medication adherence measures derived from linked administrative data and associations with mortality using restricted cubic splines in heart failure patients. Pharmacoepidemiol Drug Saf 29(2):208–218. https://doi.org/10.1002/pds.4939
Rajkumar SV (2022) Multiple myeloma: 2022 update on diagnosis, risk stratification, and management. Am J Hematol 97(8):1086–1107. https://doi.org/10.1002/ajh.26590
Ramsenthaler C, Osborne TR, Gao W, Siegert RJ, Edmonds PM, Schey SA, Higginson IJ (2016) The impact of disease-related symptoms and palliative care concerns on health-related quality of life in multiple myeloma: a multi-centre study. BMC Cancer 16:427. https://doi.org/10.1186/s12885-016-2410-2
Raoul JL, Moreau-Bachelard C, Gilabert M, Edeline J, Frénel JS (2023) Drug-drug interactions with proton pump inhibitors in cancer patients: an underrecognized cause of treatment failure. ESMO Open 8(1):100880. https://doi.org/10.1016/j.esmoop.2023.100880
Richardson PG, Laubach JP, Schlossman RL, Mitsiades C, Anderson K (2010) Complications of multiple myeloma therapy, part 1: risk reduction and management of peripheral neuropathy and asthenia. J Natl Compr Cancer Netw 8(Suppl 1):S4–s12. https://doi.org/10.6004/jnccn.2010.0115
Rosa ML, Menezes de Pádua CA, Machado TL, Drummond PLM, Silveira LP, Malta JS, Reis AM (2023) Use of drugs that induce osteoporosis or fracture in older adult with myeloma multiple: cross-sectional study. Rev Bras Farm Hosp Serv Saúde 14(2):922. https://doi.org/10.30968/rbfhss.2023.142.0922
Sánchez-Barroso L, Apellaniz-Ruiz M, Gutiérrez-Gutiérrez G, Santos M, Roldán-Romero JM, Curras M et al (2019) Concomitant medications and risk of chemotherapy-induced peripheral neuropathy. Oncologist 24(8):e784–e792. https://doi.org/10.1634/theoncologist.2018-0418
Sanfilippo KM (2020) Assessing the risk of venous thromboembolism in multiple myeloma. Thromb Res 191 Suppl 1:S74–S78. https://doi.org/10.1016/s0049-3848(20)30401-1
Sanfilippo KM, Luo S, Wang TF, Fiala M, Schoen M, Wildes TM et al (2019) Predicting venous thromboembolism in multiple myeloma: development and validation of the IMPEDE VTE score. Am J Hematol 94(11):1176–1184. https://doi.org/10.1002/ajh.25603
Schjesvold F, Oriol A (2021) Current and novel alkylators in multiple myeloma. Cancers (Basel) 13(10). https://doi.org/10.3390/cancers13102465
Schoenbeck KL, Fiala MA, Wildes TM (2021) Bortezomib in first-line therapy is associated with falls in older adults with multiple myeloma. J Geriatr Oncol 12(7):1005–1009. https://doi.org/10.1016/j.jgo.2021.02.009
SEER (2020) Cancer statistics review, 1975–2017, National Cancer Institute. https://seer.cancer.gov/csr/1975_2017/. Accessed 01 Nov 2023
Seppala LJ, Petrovic M, Ryg J, Bahat G, Topinkova E, Szczerbińska K et al (2021) STOPPFall (Screening Tool of Older Persons Prescriptions in older adults with high fall risk): a Delphi study by the EuGMS Task and Finish Group on Fall-Risk-Increasing Drugs. Age Ageing 50(4):1189–1199. https://doi.org/10.1093/ageing/afaa249
Shah UA, Mailankody S (2020) Emerging immunotherapies in multiple myeloma. BMJ 370:m3176. https://doi.org/10.1136/bmj.m3176
Shaheen NA, Alqahtani M, Alawbthani NS, Thomas A, Alaskar A (2020) Chemotherapy-induced peripheral neuropathy and its impact on health-related quality of life among multiple myeloma patients: a single-center experience. Indian J Palliat Care 26(4):506–511. https://doi.org/10.4103/ijpc.Ijpc_233_19
Sharma M, Loh KP, Nightingale G, Mohile SG, Holmes HM (2016) Polypharmacy and potentially inappropriate medication use in geriatric oncology. J Geriatr Oncol 7(5):346–353. https://doi.org/10.1016/j.jgo.2016.07.010
Silveira LP, Menezes de Pádua CA, Drummond PLM, Malta JS, Santos RMM, Costa NL et al (2022) Adherence to thalidomide in patients with multiple myeloma: a cross-sectional study in a Brazilian metropolis. J Oncol Pharm Pract 28(2):373–380. https://doi.org/10.1177/1078155221993528
Simão DAS, Teixeira AL, Souza RS, Paula Lima ED (2014) Evaluation of the Semmes-Weinstein filaments and a questionnaire to assess chemotherapy-induced peripheral neuropathy. Support Care Cancer 22(10):2767–2773. https://doi.org/10.1007/s00520-014-2275-3
Solano M, Daguindau E, Faure C, Loriod P, Pain C, Maes AC et al (2021) Oral therapy adherence and satisfaction in patients with multiple myeloma. Ann Hematol 100(7):1803–1813. https://doi.org/10.1007/s00277-021-04543-7
Staff NP, Grisold A, Grisold W, Windebank AJ (2017) Chemotherapy-induced peripheral neuropathy: a current review. Ann Neurol 81(6):772–781. https://doi.org/10.1002/ana.24951
Stein J, Geisel J, Obeid R (2021) Association between neuropathy and B-vitamins: a systematic review and meta-analysis. Eur J Neurol 28(6):2054–2064. https://doi.org/10.1111/ene.14786
Stewart C, Yrjana K, Kishor M, Soiza RL, Taylor-Rowan M, Quinn TJ et al (2021) Anticholinergic burden measures predict older People’s physical function and quality of life: a systematic review. J Am Med Dir Assoc 22(1):56–64. https://doi.org/10.1016/j.jamda.2020.05.065
Stirratt MJ, Dunbar-Jacob J, Crane HM, Simoni JM, Czajkowski S, Hilliard ME et al (2015) Self-report measures of medication adherence behavior: recommendations on optimal use. Transl Behav Med 5(4):470–482. https://doi.org/10.1007/s13142-015-0315-2
Suh Y, Ah YM, Lee E, Lee JY (2021) Association of inappropriate polypharmacy with emergency department visits in older patients receiving anti-neoplastic therapy: a population-based study. Support Care Cancer 29(6):3025–3034. https://doi.org/10.1007/s00520-020-05759-5
Sweiss K, Wirth SM, Sharp L, Park I, Sweiss H, Rondelli D, Patel PR (2018) Collaborative physician-pharmacist-managed multiple myeloma clinic improves guideline adherence and prevents treatment delays. J Oncol Pract 14(11):e674–e682. https://doi.org/10.1200/jop.18.00085
Thong BKS, Ima-Nirwana S, Chin KY (2019) Proton pump inhibitors and fracture risk: a review of current evidence and mechanisms involved. Int J Environ Res Public Health 16(9). https://doi.org/10.3390/ijerph16091571
Toci GR, Bressner JA, Morris CD, Fayad L, Levin AS (2021) Can a novel scoring system improve on the Mirels score in predicting the fracture risk in patients with multiple myeloma? Clin Orthop Relat Res 479(3):521–530. https://doi.org/10.1097/corr.0000000000001303
Toriumi S, Kobayashi A, Sueki H, Yamamoto M, Uesawa Y (2021) Exploring the mechanisms underlying drug-induced fractures using the Japanese adverse drug event reporting database. Pharmaceuticals (Basel) 14(12). https://doi.org/10.3390/ph14121299
Turner JP, Jamsen KM, Shakib S, Singhal N, Prowse R, Bell JS (2016) Polypharmacy cut-points in older people with cancer: how many medications are too many? Support Care Cancer 24(4):1831–1840. https://doi.org/10.1007/s00520-015-2970-8
Turner JP, Kantilal K, Kantilal K, Holmes HM, Koczwara B (2020) Optimising medications for patients with cancer and multimorbidity: the case for Deprescribing. Clin Oncol (R Coll Radiol) 32(9):609–617. https://doi.org/10.1016/j.clon.2020.05.015
Umıt EG, Baysal M, Bas V, Asker I, Kırkızlar O, Demır AM (2020) Polypharmacy and potentially inappropriate medication use in older patients with multiple myeloma, related to fall risk and autonomous neuropathy. J Oncol Pharm Pract 26(1):43–50. https://doi.org/10.1177/1078155219835303
van de Donk NWCJ, Pawlyn C, Yong KL (2021) Multiple myeloma. Lancet 397(10272):410–427. https://doi.org/10.1016/S0140-6736(21)00135-5
Vogel MN, Weisel K, Maksimovic O, Peters S, Brodoefel H, Claussen CD, Horger MS (2009) Pathologic fractures in patients with multiple myeloma undergoing bisphosphonate therapy: incidence and correlation with course of disease. AJR Am J Roentgenol 193(3):656–661. https://doi.org/10.2214/ajr.08.2002
Vrijens B, De Geest S, Hughes DA, Przemyslaw K, Demonceau J, Ruppar T et al (2012) A new taxonomy for describing and defining adherence to medications. Br J Clin Pharmacol 73(5):691–705. https://doi.org/10.1111/j.1365-2125.2012.04167.x
WHO (2023) WHO Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index 2023. https://www.whocc.no/atc_ddd_index/. Accessed 02 Nov 2023
Wildes TM, Maggiore RJ, Tew WP, Smith D, Sun CL, Cohen H et al (2018) Factors associated with falls in older adults with cancer: a validated model from the Cancer and Aging Research Group. Support Care Cancer 26(10):3563–3570. https://doi.org/10.1007/s00520-018-4212-3
Zajączkowska R, Kocot-Kępska M, Leppert W, Wrzosek A, Mika J, Wordliczek J (2019) Mechanisms of chemotherapy-induced peripheral neuropathy. Int J Mol Sci 20(6). https://doi.org/10.3390/ijms20061451
Zanwar S, Abeykoon JP, Kapoor P (2019) Challenges and strategies in the management of multiple myeloma in the elderly population. Curr Hematol Malig Rep 14(2):70–82. https://doi.org/10.1007/s11899-019-00500-4
Zhou L, Yu Q, Wei G, Wang L, Huang Y, Hu K et al (2021) Measuring the global, regional, and national burden of multiple myeloma from 1990 to 2019. BMC Cancer 21(1):606. https://doi.org/10.1186/s12885-021-08280-y
Ziad A, Olekhnovitch R, Ruiz F, Berr C, Bégaud B, Goldberg M et al (2018) Anticholinergic drug use and cognitive performances in middle age: findings from the CONSTANCES cohort. J Neurol Neurosurg Psychiatry 89(10):1107–1115. https://doi.org/10.1136/jnnp-2018-318190
Acknowledgments
We thank the Fundação de Amparo à Pesquisa do Estado de Minas Gerais—FAPEMIG (APQ 01816-22) for the financial support granted to the research project coordinated by AMMR.
Disclosure of Interests
All authors declare that they have no conflict of interest.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
Copyright information
© 2024 The Author(s), under exclusive license to Springer Nature Switzerland AG
About this chapter
Cite this chapter
Menezes de Pádua, C.A., Drummond, P.L.M., Malta, J.S., Silveira, L.P., Costa, I.H.F., Reis, A.M.M. (2024). Multiple Myeloma Drug Therapy: Considerations on Effectiveness and Safety. In: Interdisciplinary Cancer Research. Springer, Cham. https://doi.org/10.1007/16833_2024_252
Download citation
DOI: https://doi.org/10.1007/16833_2024_252
Published:
Publisher Name: Springer, Cham